<?xml version='1.0' encoding='utf-8'?>
<document id="28261547"><sentence text="Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities." /><sentence text="This review gives a perspective on the current &quot;state of the art&quot; in metabolic drug-drug interaction (DDI) prediction" /><sentence text=" We highlight areas of successful prediction and illustrate progress in areas where limits in scientific knowledge or technologies prevent us from having full confidence" /><sentence text="" /><sentence text="Several examples of success are highlighted" /><sentence text=" Work done for bitopertin shows how in vitro and clinical data can be integrated to give a model-based understanding of pharmacokinetics and drug interactions" /><sentence text=" The use of interpolative predictions to derive explicit dosage recommendations for untested DDIs is discussed using the example of ibrutinib, and the use of DDI predictions in lieu of clinical studies in new drug application packages is exemplified with eliglustat and alectinib"><entity charOffset="132-141" id="DDI-PubMed.28261547.s7.e0" text="ibrutinib" /><entity charOffset="270-279" id="DDI-PubMed.28261547.s7.e1" text="alectinib" /><pair ddi="false" e1="DDI-PubMed.28261547.s7.e0" e2="DDI-PubMed.28261547.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28261547.s7.e0" e2="DDI-PubMed.28261547.s7.e1" /></sentence><sentence text=" Alectinib is also an interesting case where dose adjustment is unnecessary as the activity of a major metabolite compensates sufficiently for changes in parent drug exposure"><entity charOffset="1-10" id="DDI-PubMed.28261547.s8.e0" text="Alectinib" /></sentence><sentence text=" Examples where &quot;unusual&quot; cytochrome P450 (CYP) and non-CYP enzymes are responsible for metabolic clearance have shown the importance of continuing to develop our repertoire of in vitro regents and techniques" /><sentence text=" The time-dependent inhibition assay using human hepatocytes suspended in full plasma allowed improved DDI predictions, illustrating the importance of continued in vitro assay development and refinement" /><sentence text="" /><sentence text="During the past 10 years, a highly mechanistic understanding has been developed in the area of CYP-mediated metabolic DDIs enabling the prediction of clinical outcome based on preclinical studies" /><sentence text=" The combination of good quality in vitro data and physiologically based pharmacokinetic modeling may now be used to evaluate DDI risk prospectively and are increasingly accepted in lieu of dedicated clinical studies" /><sentence text="" /></document>